Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak.
Adult
Age Factors
Aged
Betacoronavirus
/ pathogenicity
Breast Neoplasms
/ therapy
COVID-19
Clinical Trials as Topic
/ organization & administration
Continuity of Patient Care
/ organization & administration
Coronavirus Infections
/ epidemiology
Female
Humans
Infection Control
/ organization & administration
Italy
/ epidemiology
Medical Oncology
/ organization & administration
Middle Aged
Pandemics
/ prevention & control
Pneumonia, Viral
/ epidemiology
Research Design
/ standards
Risk Assessment
Risk Factors
SARS-CoV-2
Telemedicine
/ organization & administration
Breast cancer
COVID-19
SARS-CoV-2
Treatment
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
16
04
2020
accepted:
06
05
2020
pubmed:
16
5
2020
medline:
21
7
2020
entrez:
16
5
2020
Statut:
ppublish
Résumé
Northern Italy has been one of the European regions reporting the highest number of COVID-19 cases and deaths. The pandemic spread has challenged the National Health System, requiring reallocation of most of the available health care resources to treat COVID-19-positive patients, generating a competition with other health care needs, including cancer. Patients with cancer are at higher risk of developing critical illness after COVID-19 infection. Thus, mitigation strategies should be adopted to reduce the likelihood of infection in all patients with cancer. At the same time, suboptimal care and treatments may result in worse cancer-related outcome. In this article, we attempt to estimate the individual risk-benefit balance to define personalized strategies for optimal breast cancer management, avoiding as much as possible a general untailored approach. We discuss and report the strategies our Breast Unit adopted from the beginning of the COVID-19 outbreak to ensure the continuum of the best possible cancer care for our patients while mitigating the risk of infection, despite limited health care resources. IMPLICATIONS FOR PRACTICE: Managing patients with breast cancer during the COVID-19 outbreak is challenging. The present work highlights the need to estimate the individual patient risk of infection, which depends on both epidemiological considerations and individual clinical characteristics. The management of patients with breast cancer should be adapted and personalized according to the balance between COVID-19-related risk and the expected benefit of treatments. This work also provides useful suggestions on the modality of patient triage, the conduct of clinical trials, the management of an oncologic team, and the approach to patients' and health workers' psychological distress.
Identifiants
pubmed: 32412693
doi: 10.1634/theoncologist.2020-0316
pmc: PMC7272798
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1013-e1020Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : ID 21787
Pays : International
Informations de copyright
© 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Références
Breast Cancer Res Treat. 2020 Apr;180(3):747-757
pubmed: 32062784
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
CA Cancer J Clin. 2016 Jan-Feb;66(1):3-5
pubmed: 26595772
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
N Engl J Med. 2005 Oct 27;353(17):1784-92
pubmed: 16251534
JAMA Oncol. 2016 Nov 1;2(11):1477-1486
pubmed: 27367583
Lancet Oncol. 2020 Apr;21(4):e184
pubmed: 32171428
JAMA. 2020 Apr 6;:
pubmed: 32250385
Ann Surg Oncol. 2020 May;27(5):1679-1692
pubmed: 31712923
J Clin Oncol. 2020 Apr 20;38(12):1284-1292
pubmed: 32125937
JAMA Netw Open. 2020 Mar 2;3(3):e203976
pubmed: 32202646
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593